Cargando…
A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition
BACKGROUND: Paracetamol/Orphenadrine is a fixed dose combination containing 35 mg orphenadrine and 450 mg paracetamol. It has analgesic and muscle relaxant properties and is widely available as generics. This study is conducted to investigate the relative bioavailability and bioequivalence between o...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310552/ https://www.ncbi.nlm.nih.gov/pubmed/32576287 http://dx.doi.org/10.1186/s40360-020-00416-3 |
_version_ | 1783549385790980096 |
---|---|
author | Cheah, Kit Yee Mah, Kar Yee Pang, Lai Hui Ng, Shi Min Wong, Jia Woei Tan, Siew Siew Tan, Hong Zhe Yuen, Kah Hay |
author_facet | Cheah, Kit Yee Mah, Kar Yee Pang, Lai Hui Ng, Shi Min Wong, Jia Woei Tan, Siew Siew Tan, Hong Zhe Yuen, Kah Hay |
author_sort | Cheah, Kit Yee |
collection | PubMed |
description | BACKGROUND: Paracetamol/Orphenadrine is a fixed dose combination containing 35 mg orphenadrine and 450 mg paracetamol. It has analgesic and muscle relaxant properties and is widely available as generics. This study is conducted to investigate the relative bioavailability and bioequivalence between one fixed dose paracetamol/orphenadrine combination test preparation and one fixed dose paracetamol/orphenadrine combination reference preparation in healthy volunteers under fasted condition for marketing authorization in Malaysia. METHOD: This is a single-center, single-dose, open-label, randomized, 2-treatment, 2-sequence and 2-period crossover study with a washout period of 7 days. Paracetamol/Orphenadrine tablets were administered after a 10-h fast. Blood samples for pharmacokinetic analysis were collected at scheduled time intervals prior to and up to 72 h after dosing. Blood samples were centrifuged, and separated plasma were kept frozen (− 15 °C to − 25 °C) until analysis. Plasma concentrations of orphenadrine and paracetamol were quantified using liquid-chromatography-tandem mass spectrometer using diphenhydramine as internal standard. The pharmacokinetic parameters AUC(0-∞), AUC(0-t) and C(max) were determined using plasma concentration time profile for both preparations. Bioequivalence was assessed according to the ASEAN guideline acceptance criteria for bioequivalence which is the 90% confidence intervals of AUC(0-∞), AUC(0-t) and C(max) ratio must be within the range of 80.00–125.00%. RESULTS: There were 28 healthy subjects enrolled, and 27 subjects completed this trial. There were no significant differences observed between the AUC(0-∞), AUC(0-t) and C(max) of both test and reference preparations in fasted condition. The 90% confidence intervals for the ratio of AUC(0-t) (100.92–111.27%), AUC(0-∞) (96.94–108.08%) and C(max) (100.11–112.50%) for orphenadrine (n = 25); and AUC(0-t) (94.29–101.83%), AUC(0-∞) (94.77–101.68%) and C(max) (87.12–101.20%) for paracetamol (n = 27) for test preparation over reference preparation were all within acceptable bioequivalence range of 80.00–125.00%. CONCLUSION: The test preparation is bioequivalent to the reference preparation and can be used interchangeably. TRIAL REGISTRATION: NMRR- 17-1266-36,001; registered and approved on 12 September 2017. |
format | Online Article Text |
id | pubmed-7310552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73105522020-06-24 A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition Cheah, Kit Yee Mah, Kar Yee Pang, Lai Hui Ng, Shi Min Wong, Jia Woei Tan, Siew Siew Tan, Hong Zhe Yuen, Kah Hay BMC Pharmacol Toxicol Research Article BACKGROUND: Paracetamol/Orphenadrine is a fixed dose combination containing 35 mg orphenadrine and 450 mg paracetamol. It has analgesic and muscle relaxant properties and is widely available as generics. This study is conducted to investigate the relative bioavailability and bioequivalence between one fixed dose paracetamol/orphenadrine combination test preparation and one fixed dose paracetamol/orphenadrine combination reference preparation in healthy volunteers under fasted condition for marketing authorization in Malaysia. METHOD: This is a single-center, single-dose, open-label, randomized, 2-treatment, 2-sequence and 2-period crossover study with a washout period of 7 days. Paracetamol/Orphenadrine tablets were administered after a 10-h fast. Blood samples for pharmacokinetic analysis were collected at scheduled time intervals prior to and up to 72 h after dosing. Blood samples were centrifuged, and separated plasma were kept frozen (− 15 °C to − 25 °C) until analysis. Plasma concentrations of orphenadrine and paracetamol were quantified using liquid-chromatography-tandem mass spectrometer using diphenhydramine as internal standard. The pharmacokinetic parameters AUC(0-∞), AUC(0-t) and C(max) were determined using plasma concentration time profile for both preparations. Bioequivalence was assessed according to the ASEAN guideline acceptance criteria for bioequivalence which is the 90% confidence intervals of AUC(0-∞), AUC(0-t) and C(max) ratio must be within the range of 80.00–125.00%. RESULTS: There were 28 healthy subjects enrolled, and 27 subjects completed this trial. There were no significant differences observed between the AUC(0-∞), AUC(0-t) and C(max) of both test and reference preparations in fasted condition. The 90% confidence intervals for the ratio of AUC(0-t) (100.92–111.27%), AUC(0-∞) (96.94–108.08%) and C(max) (100.11–112.50%) for orphenadrine (n = 25); and AUC(0-t) (94.29–101.83%), AUC(0-∞) (94.77–101.68%) and C(max) (87.12–101.20%) for paracetamol (n = 27) for test preparation over reference preparation were all within acceptable bioequivalence range of 80.00–125.00%. CONCLUSION: The test preparation is bioequivalent to the reference preparation and can be used interchangeably. TRIAL REGISTRATION: NMRR- 17-1266-36,001; registered and approved on 12 September 2017. BioMed Central 2020-06-23 /pmc/articles/PMC7310552/ /pubmed/32576287 http://dx.doi.org/10.1186/s40360-020-00416-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Cheah, Kit Yee Mah, Kar Yee Pang, Lai Hui Ng, Shi Min Wong, Jia Woei Tan, Siew Siew Tan, Hong Zhe Yuen, Kah Hay A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition |
title | A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition |
title_full | A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition |
title_fullStr | A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition |
title_full_unstemmed | A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition |
title_short | A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition |
title_sort | randomized single-dose, two-period crossover bioequivalence study of two fixed-dose paracetamol/orphenadrine combination preparations in healthy volunteers under fasted condition |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310552/ https://www.ncbi.nlm.nih.gov/pubmed/32576287 http://dx.doi.org/10.1186/s40360-020-00416-3 |
work_keys_str_mv | AT cheahkityee arandomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT mahkaryee arandomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT panglaihui arandomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT ngshimin arandomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT wongjiawoei arandomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT tansiewsiew arandomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT tanhongzhe arandomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT yuenkahhay arandomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT cheahkityee randomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT mahkaryee randomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT panglaihui randomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT ngshimin randomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT wongjiawoei randomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT tansiewsiew randomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT tanhongzhe randomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition AT yuenkahhay randomizedsingledosetwoperiodcrossoverbioequivalencestudyoftwofixeddoseparacetamolorphenadrinecombinationpreparationsinhealthyvolunteersunderfastedcondition |